share_log

Privia Health Group Analyst Ratings

Privia Health Group Analyst Ratings

普維亞健康集團分析師評級
Benzinga Analyst Ratings ·  2023/02/03 06:27
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
02/03/2023 15.52% Goldman Sachs → $32 Initiates Coverage On → Buy
12/09/2022 1.08% Stifel → $28 Initiates Coverage On → Buy
12/08/2022 8.3% UBS → $30 Initiates Coverage On → Buy
11/11/2022 55.23% Canaccord Genuity $50 → $43 Maintains Buy
11/11/2022 40.79% SVB Leerink $46 → $39 Maintains Outperform
09/07/2022 94.95% Truist Securities $48 → $54 Assumes → Buy
08/25/2022 80.51% Canaccord Genuity $45 → $50 Maintains Buy
08/12/2022 73.29% Truist Securities $40 → $48 Maintains Buy
08/12/2022 84.12% Guggenheim $36 → $51 Maintains Buy
08/12/2022 48.01% Credit Suisse $33 → $41 Maintains Outperform
08/12/2022 58.84% Cowen & Co. $35 → $44 Maintains Outperform
08/12/2022 66.06% SVB Leerink $33 → $46 Maintains Outperform
07/14/2022 44.4% Truist Securities $36 → $40 Maintains Buy
05/13/2022 4.69% Canaccord Genuity $44 → $29 Maintains Buy
05/13/2022 19.13% Credit Suisse $43 → $33 Maintains Outperform
05/13/2022 19.13% SVB Leerink $44 → $33 Maintains Outperform
05/03/2022 -2.53% B of A Securities → $27 Initiates Coverage On → Buy
04/28/2022 26.35% BTIG → $35 Initiates Coverage On → Buy
03/30/2022 26.35% Guggenheim → $35 Initiates Coverage On → Buy
03/25/2022 58.84% SVB Leerink $43 → $44 Maintains Outperform
03/24/2022 58.84% Canaccord Genuity $50 → $44 Maintains Buy
02/22/2022 26.35% Cowen & Co. → $35 Upgrades Market Perform → Outperform
01/03/2022 19.13% Jefferies → $33 Initiates Coverage On → Buy
12/08/2021 55.23% SVB Leerink $42 → $43 Maintains Outperform
11/09/2021 51.62% SVB Leerink $35 → $42 Maintains Outperform
09/27/2021 26.35% SVB Leerink → $35 Initiates Coverage On → Outperform
09/10/2021 11.91% Cowen & Co. → $31 Initiates Coverage On → Market Perform
06/30/2021 105.78% Credit Suisse $44 → $57 Maintains Outperform
05/24/2021 44.4% JP Morgan → $40 Initiates Coverage On → Overweight
05/24/2021 44.4% Piper Sandler → $40 Initiates Coverage On → Overweight
05/24/2021 58.84% Credit Suisse → $44 Initiates Coverage On → Outperform
05/24/2021 44.4% Truist Securities → $40 Initiates Coverage On → Buy
05/24/2021 69.68% Canaccord Genuity → $47 Initiates Coverage On → Buy
05/24/2021 — William Blair Initiates Coverage On → Outperform
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
02/03/2023 15.52% 高盛 → $32 開始承保 →購買
12/09/2022 1.08% Stifel → $28 開始承保 →購買
12/08/2022 8.3% 瑞銀集團 → $30 開始承保 →購買
11/11/2022 55.23% 卡納科特·格納奇 $50 → $43 維護 買
11/11/2022 40.79% SVB Leerink $46 → $39 維護 跑贏大盤
09/07/2022 94.95% Truist證券 $48 → $54 假設 →購買
08/25/2022 80.51% 卡納科特·格納奇 $45 → $50 維護 買
08/12/2022 73.29% Truist證券 $40 → $48 維護 買
08/12/2022 84.12% 古根海姆 $36 → $51 維護 買
08/12/2022 48.01% 瑞士信貸 $33 → $41 維護 跑贏大盤
08/12/2022 58.84% 考恩公司 $35 → $44 維護 跑贏大盤
08/12/2022 66.06% SVB Leerink $33 → $46 維護 跑贏大盤
07/14/2022 44.4% Truist證券 $36 → $40 維護 買
05/13/2022 4.69% 卡納科特·格納奇 $44 → $29 維護 買
05/13/2022 19.13% 瑞士信貸 $43 → $33 維護 跑贏大盤
05/13/2022 19.13% SVB Leerink $44 → $33 維護 跑贏大盤
05/03/2022 -2.53% B of A證券 → $27 開始承保 →購買
04/28/2022 26.35% BTIG → $35 開始承保 →購買
03/30/2022 26.35% 古根海姆 → $35 開始承保 →購買
03/25/2022 58.84% SVB Leerink $43 → $44 維護 跑贏大盤
03/24/2022 58.84% 卡納科特·格納奇 $50 → $44 維護 買
02/22/2022 26.35% 考恩公司 → $35 升級 市場表現優於→
01/03/2022 19.13% 傑富瑞 → $33 開始承保 →購買
12/08/2021 55.23% SVB Leerink $42 → $43 維護 跑贏大盤
11/09/2021 51.62% SVB Leerink $35 → $42 維護 跑贏大盤
09/27/2021 26.35% SVB Leerink → $35 開始承保 →跑贏大盤
09/10/2021 11.91% 考恩公司 → $31 開始承保 →市場表現
06/30/2021 105.78% 瑞士信貸 $44 → $57 維護 跑贏大盤
05/24/2021 44.4% 摩根大通 → $40 開始承保 →超重
05/24/2021 44.4% 派珀·桑德勒 → $40 開始承保 →超重
05/24/2021 58.84% 瑞士信貸 → $44 開始承保 →跑贏大盤
05/24/2021 44.4% Truist證券 → $40 開始承保 →購買
05/24/2021 69.68% 卡納科特·格納奇 → $47 開始承保 →購買
05/24/2021 — 威廉·布萊爾 開始承保 →跑贏大盤

What is the target price for Privia Health Group (PRVA)?

Privia Health Group(PRVA)的目標價格是多少？

The latest price target for Privia Health Group (NASDAQ: PRVA) was reported by Goldman Sachs on February 3, 2023. The analyst firm set a price target for $32.00 expecting PRVA to rise to within 12 months (a possible 15.52% upside). 22 analyst firms have reported ratings in the last year.

高盛於2023年2月3日報道了Privia Health Group(納斯達克：PRVA)的最新目標價。這家分析公司將目標價定為32.00美元，預計Prva將在12個月內上漲至15.52%。過去一年，有22家分析公司公佈了評級。

What is the most recent analyst rating for Privia Health Group (PRVA)?

Privia Health Group(PRVA)的最新分析師評級是什麼？

The latest analyst rating for Privia Health Group (NASDAQ: PRVA) was provided by Goldman Sachs, and Privia Health Group initiated their buy rating.

普瑞維亞健康集團(納斯達克：PRVA)的最新分析師評級由高盛提供，普瑞維亞健康集團啟動了他們的買入評級。

When is the next analyst rating going to be posted or updated for Privia Health Group (PRVA)?

Privia Health Group(PRVA)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Privia Health Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Privia Health Group was filed on February 3, 2023 so you should expect the next rating to be made available sometime around February 3, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Privia Health Group的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Privia Health Group的上一次評級是在2023年2月3日提交的，因此您應該預計下一次評級將在2024年2月3日左右提供。

Is the Analyst Rating Privia Health Group (PRVA) correct?

分析師對Privia Health Group(PRVA)的評級正確嗎？

While ratings are subjective and will change, the latest Privia Health Group (PRVA) rating was a initiated with a price target of $0.00 to $32.00. The current price Privia Health Group (PRVA) is trading at is $27.70, which is within the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但Privia Health Group(PRVA)的最新評級是以0.00美元至32.00美元的目標價啟動的。Privia Health Group(PRVA)目前的股價為27.70美元，在分析師的預測範圍內。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論